TATAA Biocenter
TATAA Biocenter is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections.
Sponsor X4 Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A phase 3B exploratory multicenter open-label study to evaluate the effect of bimekizumab on gene expression biomarkers in study participants with moderate to severe plaque psoriasis.
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for TATAA Biocenter?
The 2026-10-09 snapshot links TATAA Biocenter to 2 distinct CTIS trials. Recorded services include Laboratory services, RT-qPCR and RNA Sequencing. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for TATAA Biocenter?
The most frequently recorded therapeutic areas are Blood Disorders, Genetic and Congenital Disorders, Immunology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to TATAA Biocenter conducted?
The linked trials record locations in 12 countries, including Germany, Poland, Belgium, Czechia, Spain. These are trial locations, not confirmed office locations or countries where TATAA Biocenter delivered services.
What can this page tell me about TATAA Biocenter's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under TATAA Biocenter. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- TATAA Biocenter AB